Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre

Patient satisfaction with the information process was high, likely due to active involvement in treatment decision-making. The results indicate that the clinical effectiveness of ranibizumab biosimilar Ongavia is comparable to ranibizumab and that it has a similar safety profile. Ongavia could serve as a cost-effective alternative, reducing healthcare system costs while maintaining high standards of patient care.